Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRM Mirum Pharmaceuticals, Inc.

Not Yet Opened 01-26 16:00:00 EST

96.92

+2.63

+2.79%

盘后96.92

+0.000.00%

17:08 EST

High98.49	Low93.23	Vol882.34K
Open96.17	D1 Closing94.29	Amplitude5.58%
Mkt Cap5.01B	Tradable Cap3.88B	Total Shares51.68M
T/O85.18M	T/O Rate2.21%	Tradable Shares39.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":96.92,"timestamp":1769461200000,"preClose":94.29,"halted":0,"volume":882340,"hourTrading":{"tag":"盘后","latestPrice":96.92,"preClose":96.92,"latestTime":"17:08 EST","volume":8760,"amount":848851.66,"timestamp":1769465322092,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02789267154523274,"floatShares":39985740,"shares":51683837,"eps":-0.83931,"marketStatus":"Not Yet Opened","change":2.63,"latestTime":"01-26 16:00:00 EST","open":96.17,"high":98.49,"low":93.23,"amount":85177212.4806,"amplitude":0.055785,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.83931,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769504400000},"marketStatusCode":0,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":94.29,"preHourTrading":{"tag":"盘前","latestPrice":97,"preClose":94.29,"latestTime":"09:08 EST","volume":124210,"amount":11711914.920400001,"timestamp":1769436486282,"change":2.71,"changeRate":0.028741,"amplitude":0.039347},"postHourTrading":{"tag":"盘后","latestPrice":96.92,"preClose":96.92,"latestTime":"17:08 EST","volume":8760,"amount":848851.66,"timestamp":1769465322092,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.031723,"impliedVol":0.3895,"impliedVolPercentile":0.3665},"requestUrl":"/m/hq/s/MIRM/tweets","defaultTab":"tweets","newsList":[{"id":"2606424896","title":"Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2606424896","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606424896?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432454,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus  to its portfolio. Brelovitug, a fully human monoclonal antibody, holds Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency. The therapy is currently being evaluated in the global AZURE Phase 3 program, with topline results expected in the second half of 2026. Mirum acquired all outstanding shares of Bluejay through a combination of cash and common stock, with potential additional tiered sales-based milestone payments. The company is also evaluating strategic options for Bluejay’s additional investigational programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL3typFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4082","BK4139","BJDX"],"gpt_icon":0},{"id":"2606217104","title":"Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217104","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217104?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:17","pubTimestamp":1769429820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 07:17 ET (12:17 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2606212542","title":"Mirum Pharmaceuticals Inc : Leerink Partners Raises Target Price to $105 From $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2606212542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606212542?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:43","pubTimestamp":1769427816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2606185214","title":"Mirum Pharmaceuticals price target raised to $130 from $102 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2606185214","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606185214?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:12","pubTimestamp":1769425924,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $102 and keeps a Buy rating on the shares. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-price-target-raised-to-130-from-102-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-price-target-raised-to-130-from-102-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2605347426","title":"HBM Healthcare Investments Reports CHF 286 Million Profit for First Nine Months of 2025/2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605347426","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605347426?lang=en_us&edition=fundamental","pubTime":"2026-01-23 13:40","pubTimestamp":1769146847,"startTime":"0","endTime":"0","summary":"HBM Healthcare Investments AG has published its Quarterly Report as at 31 December 2025, presenting key figures for the first nine months of the 2025/2026 financial year. The company reported a quarterly profit of CHF 191 million, bringing the total profit for the nine-month period to CHF 286 million. The net asset value increased by 18% during this period, while the share price rose by nearly 30%. The report notes a remaining discount of just under 20%. Significant events include the sale of a majority stake in Swixx BioPharma, after which HBM Healthcare Investments retains an approximately 8% stake in Swixx BioPharma and a 25.1% investment in Swixx Healthcare, which was spun off in 2024. The combined value growth from Swixx BioPharma and Swixx Healthcare exceeded CHF 340 million. The company also reported a negative currency effect of CHF 43 million and a decrease in the value of the funds portfolio by CHF 18 million due to currency fluctuations. HBM Healthcare Investments also benef","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDL1JCK5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2604116679","title":"Evercore ISI Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116679?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:38","pubTimestamp":1768916327,"startTime":"0","endTime":"0","summary":"In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $101.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-mirum-pharmaceuticals-mirm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-mirum-pharmaceuticals-mirm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRM"],"gpt_icon":0},{"id":"2604890438","title":"Mirum Pharmaceuticals (MIRM) Is Up 5.2% After Issuing Confident 2026 Revenue Outlook and Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2604890438","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604890438?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:24","pubTimestamp":1768782256,"startTime":"0","endTime":"0","summary":"Earlier this month, Mirum Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining its business outlook and pipeline plans to investors.\nThe company underscored 2026 revenue guidance of US$630–US$650 million and highlighted several impending late-stage clinical readouts and intellectual property actions as key business drivers.\nNext, we'll examine how Mirum's confident 2026 revenue guidance and upcoming pivotal trial readouts could reshape...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-52-after-issuing-confident","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MIRM"],"gpt_icon":0},{"id":"2604145923","title":"A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2604145923","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604145923?lang=en_us&edition=fundamental","pubTime":"2026-01-18 00:23","pubTimestamp":1768667037,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals: recent performance snapshot\nMirum Pharmaceuticals (MIRM) has attracted attention after a recent month where the share price return was 31.96%, following a 5.18% move over the past week and 23.83% over the past 3 months.\nOver the past year the stock posted a total return of 93.93%, while the year to date return stands at 16.63%. The shares last closed at US$91.05, with an intrinsic value estimate implying a 68.82% discount.\nSee our latest analysis for Mirum...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/a-look-at-mirum-pharmaceuticals-mirm-valuation-after-strong-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/a-look-at-mirum-pharmaceuticals-mirm-valuation-after-strong-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2604919621","title":"Director Saira Ramasastry Reports Disposal of Mirum Pharmaceuticals Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919621","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919621?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:06","pubTimestamp":1768597560,"startTime":"0","endTime":"0","summary":"Saira Ramasastry, Director at Mirum Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL9vCkBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Saira Ramasastry Reports Disposal of Mirum Pharmaceuticals Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2603105684","title":"Mirum Pharmaceuticals Price Target Raised to $102.00/Share From $81.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603105684","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603105684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:14","pubTimestamp":1768310040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 08:14 ET (13:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2603683131","title":"Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2603683131","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603683131?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:15","pubTimestamp":1768302928,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $102 from $81 and keeps a Buy rating on the shares. The company p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-price-target-raised-to-102-from-81-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-price-target-raised-to-102-from-81-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2603952116","title":"Mirum Pharmaceuticals Grants Stock Options and RSUs to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2603952116","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603952116?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:30","pubTimestamp":1768257011,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals Inc. announced that it has granted inducement awards to five new employees under its 2020 Inducement Plan. The awards include non-qualified stock options to purchase 4,900 shares of common stock at an exercise price of $86.57 per share, and 6,500 restricted stock units . The stock options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The RSUs vest over three years, with one-third vesting on each anniversary of the vesting commencement date. These awards are subject to the terms and conditions of the 2020 Inducement Plan and the respective award agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL94z3RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2603521957","title":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603521957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603521957?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:30","pubTimestamp":1768257000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9MCHDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2603130523","title":"Baird Adjusts Mirum Pharmaceuticals Price Target to $95 From $88, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603130523","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603130523?lang=en_us&edition=fundamental","pubTime":"2026-01-13 03:37","pubTimestamp":1768246636,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals (MIRM) has an average rating of buy and mean price target of $95.63, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2602754849","title":"BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754849","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602754849?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:35","pubTimestamp":1768224939,"startTime":"0","endTime":"0","summary":"BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline MomentumJan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7B5LSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2602548430","title":"Mirum Pharmaceuticals Projects 2026 Global Net Product Sales of Up to $650 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548430","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548430?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:35","pubTimestamp":1768224936,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals Inc. announced that its preliminary unaudited net product sales for 2025 are approximately $520 million, exceeding the upper end of its guidance. For 2026, the company expects global net product sales to be between $630 million and $650 million, reflecting continued strong commercial growth. The financial outlook highlights significant year-over-year growth and underscores the company’s momentum in both commercial performance and pipeline advancement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLNsyf8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2602548150","title":"Mirum Pharmaceuticals Inc - Livmarli Expand Study in Additional Cholestatic Pruritus Settings Timing Accelerated; Topline Data NOW Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548150?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7B5LSS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2602481895","title":"Mirum Pharmaceuticals Inc - Prelim 2025 Net Product Sales of Approximately $520 Mln Exceed Upper End of Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602481895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602481895?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7B5LSS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"2602354818","title":"Mirum Pharmaceuticals Inc - Volixibat Vistas Study in Primary Sclerosing Cholangitis (Psc) Topline Data Expected Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602354818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602354818?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7B5LSS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2602144548","title":"Mirum Pharmaceuticals - Bluejay Therapeutics' Azure-1 Study in Hdv Interim Data Expected in Q2 2026, Topline Phase 3 Data Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602144548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602144548?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7B5LSS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":0.0645},{"period":"1month","weight":0.2228},{"period":"3month","weight":0.3746},{"period":"6month","weight":0.8959},{"period":"1year","weight":1.0391},{"period":"ytd","weight":0.227}],"compareEarnings":[{"period":"1week","weight":0.0015},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0083},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.1394},{"period":"ytd","weight":0.0159}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054716},{"month":2,"riseRate":0.833333,"avgChangeRate":0.061659},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.05038},{"month":4,"riseRate":0.5,"avgChangeRate":0.059141},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.035958},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097654},{"month":7,"riseRate":0.666667,"avgChangeRate":0.076249},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.315468}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mirum Pharmaceuticals, Inc.(MIRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mirum Pharmaceuticals, Inc.(MIRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}